Phase 1: Early CKD (G3a, eGFR 45–59)

Trigger: Nephron loss → ↓ filtered load of phosphate

Compensatory response: 1. FGF23 ↑↑ (fibroblast growth factor 23) - Secreted by osteoblasts/osteocytes in response to ↓ GFR + ↑ phosphate - Early marker of dysregulation; may ↑ before serum PO4 rises - Suppresses PTH, ↑ FGF23-mediated phosphate excretion - Inhibits 1,25-(OH)2 vitamin D (active vitamin D) synthesis

2. PTH rises slightly (phosphate retention drives PTH)
   • ↑ Serum PTH → ↑ phosphate excretion per remaining nephron
   • Net effect: Serum PO4 stays NORMAL for longer
3. Serum phosphate remains NORMAL (~3.5–4.5 mg/dL)

Phase 2: Moderate-to-Advanced CKD (G3b–G4, eGFR 15–44)

Worsening phosphate retention: - More nephrons lost → even with ↑↑ FGF23, phosphate accumulates - Serum phosphate begins to rise (>4.5 mg/dL)

PTH escalation: - Combines effects of: hyperphosphatemia + ↓ 1,25(OH)2 vitamin D (low calcium) + persistent FGF23 - PTH ↑↑↑ (may exceed 100 pg/mL)

Vitamin D metabolism disrupted: - ↓ 1,25-(OH)2 vitamin D (active form) - Normally produced by proximal tubule with FGF23 suppression - FGF23 ↑↑ → ↓↓ 1,25(OH)2D synthesis - ↓ 1,25(OH)2D → ↓ intestinal calcium absorption → ↓ serum Ca → ↑ PTH (vicious cycle)

• ↑ 25-OH vitamin D may be normal — stored form less affected (but may be low from poor nutrition/sun exposure)

Result: Secondary hyperparathyroidism (2° HPT) — PTH elevated due to CKD-induced stimuli

Phase 3: Advanced CKD & ESRD (G5, eGFR <15)

Overt hyperphosphatemia: PO4 >5 mg/dL

Tertiary hyperparathyroidism: PTH becomes autonomous - Even if phosphate, calcium normalize, PTH remains ↑ (from years of stimulation + parathyroid gland hyperplasia)

Calcification risk: Calcium/phosphate loading and active vascular mineralization contribute to arterial and valvular disease. Assess calcium and phosphate individually with PTH trends; a calcium–phosphate product of 55 is not a universal risk or treatment threshold.

Bone disease spectrum: 1. High-turnover bone disease (secondary HPT) - Excessive PTH → osteoblast & osteoclast activity ↑ - Rapid remodeling, loss of cortical bone, trabecular preservation 2. Low-turnover bone disease (adynamic bone) - Suppressed PTH (over-treatment with vitamin D, calcimimetics) - Minimal bone remodeling → impaired fracture healing 3. Mixed uremic osteodystrophy — elements of both

When to Start Monitoring

Shorten intervals for changing values, symptoms, or treatment changes. KDIGO CKD-MBD guidance.

Key Lab Parameters

CKD G3a–G3b (eGFR 30–59)

Goal: Prevent secondary HPT development

1. Phosphate restriction
   • Diet: Review phosphate additives and overall intake with a renal dietitian while preserving adequate nutrition; individualize restriction when phosphate is persistently elevated.
   • No binders needed yet if serum PO4 normal
2. Vitamin D repletion (if 25-OH VitD <30)
   • Ergocalciferol (Vitamin D2) 50,000 IU weekly × 12 weeks, then monthly
   • OR Cholecalciferol (Vitamin D3) 1,000–2,000 IU daily
   • Goal: 25-OH VitD 30–100 ng/mL
3. Monitor PTH trend
   • If PTH rises progressively or remains above the assay limit, assess phosphate intake, phosphate, calcium, and vitamin D. A mild single rise is not an automatic calcitriol indication.
4. Calcium neutral approach — avoid hypercalcemia

CKD G4 (eGFR 15–29)

Goal: Control PTH, phosphate; prevent vascular calcification

1. Phosphate-lowering treatment: Base initiation on progressively or persistently elevated phosphate, assessed together with calcium and PTH; do not use one phosphate value as an automatic binder order.
   • Calcium-based: Calcium carbonate, calcium acetate
     • Pro: Inexpensive, help with acidosis
     • Con: Calcium loading can increase hypercalcemia and calcification risk; restrict calcium-based binder exposure in adults and individualize selection without a calcium–phosphate product cutoff.
   • Non-calcium: Sevelamer, lanthanum, sucroferric oxyhydroxide
     • Pro: Don’t ↑ Ca; may ↓ phosphate absorption better
     • Con: Expensive, GI tolerability, multiple daily doses
   Key Point

   Modern trend: Avoid calcium-based binders in late CKD; prefer non-calcium agents to minimize Ca load and vascular calcification risk.

2. Active vitamin D: Do not use routinely in adult nondialysis CKD. In G4–G5, reserve consideration for severe, progressive hyperparathyroidism after addressing modifiable factors; individualize dose and monitor calcium/phosphate. A PTH cutoff of 110 or a calcium–phosphate product below 55 is not a treatment rule.
3. Calcimimetics: Principally a G5D PTH-lowering option with calcium monitoring. Do not automatically apply a dialysis regimen to nondialysis G4; specialist selection considers the indication, calcium/phosphate, treatment effects, and product labeling.
4. Monitoring in G4: Calcium/phosphate generally every 3–6 months and PTH every 6–12 months; assess more often when abnormalities or treatment changes warrant it.

CKD G5D (dialysis): distinguish dialysis treatment from G5 not receiving dialysis.

Goal in G5D: Evaluate PTH against the assay upper limit and its trajectory; avoid treatment oversuppression while addressing persistently elevated phosphate and calcium loading.

1. Dialysis phosphate removal
   • Depends on GFR, urine output, residual kidney function
   • Phosphate removal varies with delivered dialysis duration/frequency, rebound, intake and residual kidney function; assess adequacy in the individual patient.
2. Aggressive phosphate management
   • Binders with meals: Non-calcium preferred (sevelamer, lanthanum)
   • Dietary PO4 restriction <1,000 mg/day
   • Avoid high-phosphate foods (colas, processed meats, dairy)
3. Dialysis PTH framework: Approximately 2–9 times the assay upper limit, with substantial directional changes prompting reassessment; no universal 150–300 pg/mL target applies to every assay.
4. Calcium balance
   • Avoid hypercalcemia (Ca >10 mg/dL)
   • Consider low-Ca dialysate if hypercalcemia
5. Bone biopsy (if unexplained bone pain, fractures, or concern for adynamic bone)
   • Tetracycline labeling → assess turnover, mineralization
   • Guides intensity of therapy

FGF23 Antagonists (Research phase)

• Direct FGF23 blockade is not established routine treatment for CKD-MBD. Do not extrapolate therapies for hypophosphatemic disorders to CKD phosphate retention.

Phosphate Binders (Newer generation)

• Sucroferric oxyhydroxide is an iron-based phosphate binder administered with meals according to its label; it is not a once-daily regimen.
• Patiromer treats hyperkalemia; it is not a substitute for an indicated phosphate-lowering treatment.

Screening for Osteoporosis in CKD

• DXA/BMD testing: In G3a–G5D with CKD-MBD or osteoporosis risk factors, obtain BMD testing when the result will affect treatment decisions. DXA does not determine the renal bone-turnover subtype; assess that question separately.
• Combine fracture history, falls risk, relevant biochemistry, and BMD when it will change management; consider specialist bone-turnover assessment when needed.

Management

1. Exercise and nutrition: Encourage safe weight-bearing activity and adequate nutrition. Protein needs differ between nondialysis CKD and dialysis; individualize with a renal dietitian.
2. Calcium balance: Avoid both hypo- and hypercalcemia
3. Vitamin D: Maintain 25-OH VitD >30 ng/mL
4. Antifracture therapy in advanced CKD requires assessment of kidney function, CKD-MBD, likely turnover and the selected drug label; use specialist input rather than a blanket regimen.
5. Consider anabolic agents (PTH analogues) if documented low-turnover bone on biopsy (rare, specialized)

Mechanisms of Vascular Calcification in CKD

1. Mineral deposition: Calcium and phosphate loading contribute to vascular mineral deposition, but a product of 55 is not a universal precipitation or treatment threshold.
2. Active osteogenic conversion: Vascular smooth muscle cells transdifferentiate → osteoblast-like → produce mineralization matrix
3. Loss of calcification inhibitors: ↓ Fetuin-A, matrix Gla protein (MGP)
4. Oxidative stress & inflammation from uremia

Prevention

• Treat progressively or persistently elevated phosphate, aiming to lower elevated values toward the normal range while considering calcium and PTH together.
• Use the individual calcium and phosphate values rather than a calcium–phosphate product target.
• Avoid excess calcium supplementation
• Use non-calcium binders
• Manage inflammation (dialysis adequacy)